Sustained-release buprenorphine is a safe and effective treatment for pregnant and postpartum women with opioid use disorder[1]. The study included 15 pregnant and postpartum patients who were treated with this drug[1]. The main reasons for starting treatment with sustained-release buprenorphine were nausea, the difficulty of multiple daily dosing of sublingual buprenorphine, and persistent opioid cravings[1]. After initiation of treatment, all patients demonstrated increased adherence to treatment, complete cessation of non-prescribed opioid use, and reduction in other substance use[1]. The study did not report any adverse effects on the mother or the newborn[1]. Buprenorphine during pregnancy and in the postpartum period reduces maternal and fetal morbidity and mortality[1].